Opus Genetics, Inc. (IRD) Reports Q3 Loss, Beats Revenue EstimatesZacks Investment Research • 11/12/25
Opus Genetics Announces Financial Results for Third Quarter 2025 and Provides Corporate UpdateGlobeNewsWire • 11/12/25
Opus Genetics Announces Successful FDA Meeting Supporting Advancement of OPGx-LCA5 Toward Pivotal Trial for LCA5-Related Inherited Retinal DiseaseGlobeNewsWire • 11/06/25
Opus Genetics, Inc. (IRD) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseZacks Investment Research • 11/04/25
Opus Genetics to Participate in Chardan's 9th Annual Genetic Medicines ConferenceGlobeNewsWire • 10/14/25
Opus Genetics to Present at Upcoming Medical and Industry Conferences in October 2025GlobeNewsWire • 10/02/25
Are You Looking for a Top Momentum Pick? Why Opus Genetics, Inc. (IRD) is a Great ChoiceZacks Investment Research • 10/01/25
Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5)GlobeNewsWire • 09/30/25
Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast ConditionsGlobeNewsWire • 09/04/25
Opus Genetics to Participate in the H.C. Wainwright 27th Annual Global Investment ConferenceGlobeNewsWire • 09/03/25
Opus Genetics Inherited Retinal Disease Programs Featured at Medical and Industry Conferences in SeptemberGlobeNewsWire • 08/27/25
Opus Genetics Announces FDA Clearance of IND Application for Gene Therapy Candidate OPGx-BEST1GlobeNewsWire • 08/18/25
Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate UpdateGlobeNewsWire • 08/13/25
Opus Genetics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual ConferenceGlobeNewsWire • 08/05/25
Opus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood BlindnessGlobeNewsWire • 07/23/25
Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 07/03/25
Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of PresbyopiaGlobeNewsWire • 06/26/25
Opus Genetics Awarded Non-Dilutive Funding from the RD Fund to Support Preclinical Development of OPGx-MERTK ProgramGlobeNewsWire • 06/23/25
Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast ConditionsGlobeNewsWire • 06/02/25
Opus Genetics, Inc. (IRD) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 05/15/25
Opus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate UpdateGlobeNewsWire • 05/15/25